Recurrent C. diff: Using Real-World Data to Guide Treatment Strategies

Sponsored by: FERRING PHARMACEUTICALS

In honor of C. diff Awareness Month, the IDSA Foundation hosted a webinar that provided the latest insights on recurrent Clostridioides difficile infection. The session highlighted real-world outcomes from newly approved gut microbial therapies and offered a comprehensive look at the ongoing challenges posed by C. diff, recognized as one of the top five most urgent public health threats. Specialists discussed the current landscape of C. diff infections and explored innovative approaches to reducing recurrence, focusing on the benefits of GMT. This webinar provided health care professionals with an opportunity to deepen their understanding of the epidemiology, treatment advancements and patient care considerations surrounding rCDI.